Clinical Gastroenterology, Digestive Diseases, Fatty Liver, Gastroenterology, Hepatitis, Hepatocellular Cancer, Jaundice, Liver Cancer, Liver Disease, Liver Mass, Liver Test Abnormalities, Liver Transplant, Liver Transplant Evaluation, Liver Tumors, Nonalcoholic Steatohepatitis, Sclerosing Cholangitis, Viral Hepatitis, Acute or Chronic
In the fall of 2012, Saleh Alqahtani, M.D. joined the Johns Hopkins Division of Gastroenterology & Hepatology following a successful tenure on the faculty of the University of Texas Southwestern Medical Center in Dallas, Texas. Dr. Alqahtani also served as Instructor in Medicine at Mayo Clinic, Rochester, Minnesota. In joining the Johns Hopkins faculty, Dr. Alqahtani is part of a team of renowned scientists with a track record of success in developing leading-edge methods for addressing the complexities of liver disease, with examples of some of these accomplishments noted above.
Dr. Alqahtanis primary research focus is on the third most common cancer in the world, that of the liver. The prognosis for this form of cancer is almost always fatal. Currently, the majority of treatments are suboptimal and for patients with small liver cancers and significant associated liver disease, transplantation, which has its own limitations, offers the only option for a cure. Building on the expertise and scientific resources available at Johns Hopkins, Dr. Alqahtani will advance discovery in the following aspects of liver cancer:
Development of new, effective approaches to treatment; Identification of methods for the early detection (using among other tools, mini-peritneoscopy) and prevention.
The treatments for Hepatitis B and C are often accompanied by severe, debilitating side effects. These diseases also leave patients with an increased likelihood of developing liver cancer. Because of the close inter-relationship between Hepatitis B and C and liver cancer, Dr. Alqahtani also plans to dedicate efforts to the development of new treatments for these diseases.